文献速递白血病淋巴瘤

双重STAT3/STAT5抑制作为T幼淋巴细胞白血病的新型治疗策略

Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.
PubMed 文献 · Leukemia · 2025-04-15

该研究整合基因组数据与转录组分析,在335例T-PLL中发现以JAK3和STAT5B为主的复发性JAK/STAT突变,且几乎所有样本存在JAK/STAT组成性激活。先导化合物JPX-1244可选择性诱导原代T-PLL细胞死亡,STAT3/STAT5降解程度与细胞毒性直接相关。克拉屈滨、维奈克拉和阿扎胞苷为最有效联合伙伴,均可协同降低STAT5磷酸化。

要点

  • 335例T-PLL中JAK/STAT突变以JAK3和STAT5B为主,几乎所有样本存在JAK/STAT组成性激活。
  • JPX-1244通过阻断STAT3/STAT5磷酸化并诱导其降解,选择性杀伤原代T-PLL细胞。
  • 克拉屈滨、维奈克拉和阿扎胞苷与STAT3/STAT5降解剂协同降低STAT5磷酸化。

核心结论

  • 双重STAT3/STAT5抑制,尤其与去甲基化药物和BCL2靶向药物联合,是T-PLL有前景的干预策略,需进一步研究。

研究设计与样本

  • 整合基因组数据与新的转录组分析,在335例T-PLL病例队列中鉴定复发性JAK/STAT突变。
  • 评估双重STAT3/STAT5非PROTAC降解剂(先导物质JPX-1244)在原代T-PLL样本中的抗白血病潜力,并进行后续联合筛选。

主要发现

  • 复发性JAK/STAT突变主要位于JAK3和STAT5B;转录组和蛋白分析显示几乎所有样本存在JAK/STAT组成性激活。
  • JPX-1244高效、选择性地诱导原代T-PLL样本(包括对常规治疗耐药者)细胞死亡,机制为阻断STAT3和STAT5磷酸化并诱导其降解。
  • STAT3/STAT5降解程度与细胞毒性直接相关;RNA测序证实治疗相关下调STAT5靶基因。
  • JAK/STAT突变不能预测药理学STAT3/STAT5降解的应答;TOX、PAK6和SPINT1表达升高与药物敏感性相关。
  • 联合筛选中克拉屈滨、维奈克拉和阿扎胞苷为最有效联合伙伴,即使在低应答T-PLL样本中也协同降低STAT5磷酸化。

局限性

  • 原文结论指出该干预策略需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-prolymphocytic leukemia (T-PLL) is a rare, aggressive T-cell malignancy with poor outcomes and an urgent need for new therapeutic approaches. Integrating genomic data and new transcriptomic profiling, we identified recurrent JAK/STAT mutations (predominantly in JAK3 and STAT5B) as hallmarks in a cohort of 335 T-PLL cases. In line, transcriptomic and protein analyses revealed constitutive JAK/STAT activation in virtually all samples. Consequently, we explored the anti-leukemic potential of dual STAT3/STAT5 non-PROTAC degraders in T-PLL, with JPX-1244 as our lead substance. JPX-1244 efficiently and selectively induced cell death in primary T-PLL samples, including those resistant to conventional therapies, by blocking STAT3 and STAT5 phosphorylation and by inducing their degradation. The extent of STAT3/STAT5 degradation directly correlated with cytotoxicity. RNA-sequencing confirmed the treatment-related downregulation of STAT5 target genes. While JAK/STAT mutations did not predict responses to pharmacologic STAT3/STAT5 degradation, elevated expression of TOX, PAK6, and SPINT1 were associated with drug sensitivity. In subsequent combination screenings, cladribine, venetoclax, and azacytidine emerged as most effective combination partners of STAT3/STAT5 degraders, even in low-responding T-PLL samples, all synergistically reducing STAT5 phosphorylation. These findings highlight dual STAT3/STAT5 inhibition, particularly in combination with hypomethylating and BCL2-targeting agents, as a promising interventional approach in T-PLL, warranting further investigation.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dechow A, Timonen S, Ianevski A, et al. Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia. Leukemia. 2025. PMID: 40234614. doi:10.1038/s41375-025-02577-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。